(Press-News.org) The published data provide additional detail of an initial analysis conducted in January, while more robust data from a complete analysis of the study was subsequently shared in March 2021.
Publication of initial primary analysis highlights cross-protection by the Novavax Covid-19 vaccine against the B.1.351 variant prevalent in South Africa during the study.
This is the first published study to show protection against mild Covid-19 caused by the B.1.351 variant circulating in South Africa.
An updated analysis of the study indicated 100% protection against severe Covid-19 due to the B.1.351 variant.
"An efficacy of 50% is sufficient to meet the World Health Organization criteria for regulatory approval of the vaccine," says Madhi.
The Novavax Covid-19 vaccine, known as NVX-CoV2373, is made by Novavax, Inc., a US-based biotechnology company developing next-generation vaccines for serious infectious diseases.
Gregory M. Glenn, M.D., President of Research and Development, Novavax, says: "This data publication reinforces the encouraging safety profile and cross-protective effect across variants seen in studies of our vaccine to-date."
ABOUT THE STUDY
The Phase 2b randomised, observer-blinded, placebo-controlled trial conducted in South Africa evaluated efficacy, safety and immunogenicity in healthy adults, and in a small cohort of medically stable adults living with human immunodeficiency virus (HIV).
The study met its primary endpoint - i.e., the Novavax vaccine demonstrated an overall efficacy of 49% in the initial analysis (published in NEJM), and 49% in the subsequent complete analysis (unpublished).
Among healthy adults without HIV, the Novavax vaccine demonstrated efficacy of 60% in the initial analysis, and 55% in the subsequent complete analysis.
In the initial analysis, cases were predominantly mild-to-moderate and due to the B.1.351 variant that dominates in South Africa, and increasingly in southern Africa.
In the subsequent complete analysis, circulation of the B.1.351 variant continued to dominate, and all five cases of severe disease observed in the trial occurred in the placebo group.
The initial analysis, now being published in NEJM, suggested that prior infection with the original Covid-19 strain did not protect against subsequent infection by the variant predominantly circulating in South Africa through 60 days of follow-up.
However, with additional follow-up, the complete analysis of the South Africa trial indicates that there may be a modest protective effect of prior exposure with the original Covid-19 strain.
Among placebo recipients, at 90 days of follow-up, the illness rate was 8.0% in baseline seronegative participants and 5.9% in baseline seropositive participants.
"The data make a compelling case for use of the Novavax Covid-19 vaccine in settings where the B.1.351 variant dominates - which is most of southern Africa - to reduce the risk of mild disease and also to maximise the opportunity for protection against severe Covid," says Madhi. "Further work is required for Novavax and all other Covid-19 vaccines, particularly in people living with HIV."
The Novavax Covid-19 vaccine trial is one of two Covid-19 vaccine trials in South Africa led by Madhi and Wits VIDA, with the other being the Oxford/AstraZeneca Covid-19 vaccine trial.
In addition to directing Wits VIDA, Madhi is Dean of the Faculty of Health Sciences at the University of the Witwatersrand, Johannesburg (Wits), and co-Director of African Leadership in Vaccinology Expertise (ALIVE).
ABOUT THE WITS VACCINES & INFECTIOUS DISEASES ANALYTICS (VIDA) RESEARCH UNIT
Formerly known as the Respiratory and Meningeal Pathogens Research Unit (RMPRU) and founded in 1995, the Vaccines and Infectious Diseases Analytics (VIDA) Research Unit of the University of the Witwatersrand (Wits) is an internationally recognised, African-led research unit in the field of epidemiology of vaccine preventable diseases, and clinical development of life-saving vaccines.
Under the guidance of Professor Shabir Madhi, a global leader in the field of paediatric infectious diseases and the Dean of the Faculty of Health Sciences at Wits University, Wits VIDA is conducting translational research on vaccine preventable diseases and training the next generation of clinician scientists.
Combining clinical, microbiological and epidemiological expertise in an African setting, Wits VIDA's cutting-edge scientific research informs local and global policy recommendations on the use of next-generation and novel vaccines today.
In addition to various other studies on Covid-19, Wits VIDA championed and led the first two Covid-19 vaccine trials in Africa in 2020, for the Oxford and Novavax vaccine candidates.
INFORMATION:
ABOUT THE NOVAVAX VACCINE KNOWN AS NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes Covid-19 disease.
NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause Covid-19. In pre-clinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease.
It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.
NVX-CoV2373 is stored and stable at two degrees Celsius to eight degrees Celsius, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
UNIVERSITY PARK, Pa. -- Social media has become a platform for new mothers to openly share their experiences of the joys and challenges of parenthood. Researchers at Penn State and Dalhousie University have unraveled the sentiments in nursing mothers' tweets to better understand the factors influencing breastfeeding behaviors. They hope the findings can inform policies and interventions to support and improve resources for nursing mothers, such as breastfeeding support, workplace accommodations and technological aids such as apps.
"We are getting the raw sentiment of nursing mothers without putting them in a controlled experiment environment ...
The world's first-ever 'academic paper which is not a paper' is due to be presented by a Lancaster University research team at the premier international conference on human-computer interaction.
Dr Joseph Lindley, a researcher at Lancaster University's ImaginationLancaster design-led research laboratory, Dr Miriam Sturdee, from the University's School of Computing and Communications, Senior Research Associate Dr David Green and Research Associate Hayley Alter have been invited to take part in the 2021 ACM CHI Virtual Conference on Human Factors in Computing Systems in May.
Using the innovative 'Gather Town' online video-calling and conferencing platform, they have experimented in setting up a conference paper as an interactive but virtual ...
Clinical practice guidelines for dealing with the physical and mental health of transgender people highlight the current lack of a solid research base which must be improved, according to a new study published in the journal BMJ Open.
A team of researchers from Anglia Ruskin University (ARU) and King's College London searched world literature for all international clinical practice guidelines on the healthcare needs of gender minority and trans people.
Results showed that higher quality guidelines tended to focus mainly on HIV, and most others were on transition-related interventions. There were noticeable gaps in the topics of guidelines, with none addressing ...
An article published in International Journal of Hyperthermia proposes a more effective protocol for the treatment of cardiac arrhythmias when applying radiofrequency energy at the site of the arrhythmia by catheterization. The research results from the final year project (TFG) on the bachelor's degree in Biomedical Engineering by Sergi Coderch Navarro, supervised by Ana González Suárez and Oscar Camara, researchers with the PhySense group of the BCN MedTech Research Unit at the UPF Department of Information and Communication Technologies (DTIC). Sergi Coderch Navarro defended his TFG in July 2019 and was a runner-up in the 2019 Gemma Rossell i Romero Awards. Currently, Ana González Suárez is a postdoctoral ...
Scientists at Tokyo Institute of Technology experimentally verify the existence of exotic surface conduction states in topological semimetals (TSMs), materials that lie at the boundary between conductors and insulators, by performing voltage scans of these surface states on a thin film sample of a TSM. The findings can pave the way for future study and exploitation of such conduction states in realizing novel, quantum transport phenomena.
All of us are probably familiar with the idea of conductors and insulators. But what would you call a material that can conduct on the surface but insulate on the inside? Physicists call it a "topological insulator" (TI), a term that highlights the geometric aspect of its strange conduction behavior. Even stranger ...
ITHACA, N.Y. - Solar-power developers need to explore using lower-quality agricultural land for solar energy, incentivize dual-use (combined agriculture and solar) options, avoid concentrated solar development and engage communities early to achieve New York's green energy goals, according to forthcoming Cornell University research.
"As farmland is generally flat and cleared, agricultural land will be the prime target for future solar energy development," said Max Zhang, professor in the Sibley School of Mechanical and Aerospace Engineering. "Good farmland, however, is not ideal."
Zhang is senior author of "Strategic Land Use Analysis for Solar Energy Development in New York State," which will publish in August 2021 in Renewable Energy.
Under New York state's 2019 Climate ...
A recent study analyses data collect4d at 44 of the darkest places in the world, including the Canary Island Observatories, to develop the first complete reference method to measure the natural brightness of the night sky using low-cost photometers.
Of the 44 photometers in the survey, the Roque de los Muchachos Observatory (Garafía, La Palma, Canary Islands) stands out at the darkest of all the skies analysed.
The night sky is not completely dark; even in the remotest places there is a glow in the sky produced by natural components, both terrestrial and extraterrestrial, ...
They are 50,000 times thinner than a human hair, and just a few atoms thick: two-dimensional materials are the thinnest substances it is possible to make today. They have completely new properties and are regarded as the next major step in modern semiconductor technology. In the future they could be used instead of silicon in computer chips, light-emitting diodes and solar cells. Until now, the development of new two-dimensional materials has been limited to structures with layers of rigid chemical bonds in two spatial directions - like a sheet of paper in a stack. Now for the first time, a research team from the ...
Philadelphia, May 6, 2021--Researchers have found an independent association between COVID-19-related income loss and financial strain and depression, according to the latest study from the COVID-19 Resilience Project, run by the Lifespan Brain Institute (LiBI) of Children's Hospital of Philadelphia (CHOP) and Penn Medicine. This association was found in two separate cohorts - one primarily in the United States and one in Israel - and the depressive symptoms worsened over time in participants who were hit financially, above and beyond pandemic-related anxiety. The findings were published today in the Journal of Affective Disorders.
"This study is an important first step in understanding the unique ...
(Boston)-- The global spread of COVID-19 has raised serious concern for patients with chronic disease. A correlation has been identified between the severity of COVID-19 and a patient's preexisting comorbidities. Although COVID-19 primarily involves the respiratory system, dysfunction in multiple organ systems is common, particularly in the cardiovascular, gastrointestinal, immune, renal, and nervous systems. Patients with transthyretin amyloidosis (ATTR) (a disease caused by an abnormal misfolded protein that causes buildup of amyloid deposits in the heart, peripheral nervous system including the autonomic nervous system, or other organs) represent a population particularly vulnerable to COVID-19 morbidity due to the multisystem nature of ATTR amyloidosis.
Early ...
